Ambrx Biopharma Cayman, Inc.: key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2022): $7.4M
Net Income/Loss (FY2022): -$78.0M
Total Assets (FY2022): $147.0M
Total Equity (FY2022): $117.8M
Cash Flows from Operating Activities (FY2022): -$68.7M

Source: Ambrx Biopharma Cayman, Inc. 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.

Ambrx Biopharma Cayman, Inc. Financials | Hub-Equity